Clinical trials
PSMA clinical trials
Below are recruiting psma clinical trials, each written for real people, not researchers. We’re tracking 197 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06931340RecruitingPhase 3
Adding chemo to hormone therapy for advanced prostate cancer
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
Tucson, ArizonaAges 18 years+ - NCT06632977RecruitingPhase 2
Matching targeted treatments to your prostate cancer's genetics
This trial is testing whether matching your cancer's specific genetic changes to a targeted treatment can help control metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. You may receive a drug, a radioactive treatment, or a combination based on your tumor's molecular profile.
Birmingham, AlabamaAges 18 years+ - NCT05438563Recruiting
MRI-guided prostate cancer ablation with ultrasound from the urethra
This trial tests a newer way to treat certain low- to intermediate-risk prostate cancers using MRI guidance and an ultrasound probe placed through the urethra. It aims to destroy the tumor while using imaging to help target it more precisely.
Rochester, MinnesotaAges 45–80 - NCT07707232Recruiting
Using AI to read PSMA PET/CT reports for prostate cancer
This trial uses a computer program (large language model) to help doctors read Chinese PSMA PET/CT reports. The goal is to see if the AI can accurately identify key details about prostate cancer, like where it has spread, which may help make staging and treatment decisions faster.
Wenzhou, ZhejiangAges 18 years+ - NCT06039371RecruitingPhase 2
High dose testosterone during chemo for advanced prostate cancer
This trial tests if adding high doses of testosterone to standard chemotherapy (etoposide and carboplatin) can make the chemo work better in men whose prostate cancer has stopped responding to other treatments. It aims to see if this approach can shrink tumors or slow cancer growth.
Seattle, WashingtonAges 18 years+ - NCT03185468RecruitingPhase 1/Phase 2
CAR-T cell therapy for advanced bladder cancer
This Phase 1/2 trial tests CAR-T therapy—a treatment where immune cells are changed to better attack cancer—for bladder cancer that has spread or grown locally. It may help shrink tumors and control the disease by boosting a patient’s immune response.
Shenzhen, GuangdongAges 18–65 - NCT03198052RecruitingPhase 1
CAR-T cell therapy for cancers with specific protein targets
This Phase 1 study tests CAR-T cells that are engineered to recognize several cancer “markers” (specific proteins) found on some advanced cancers. It may help by directing the patient’s own immune cells to attack cancer, but eligibility depends on matching the required protein markers.
Guangzhou, GuangdongAges 18–75 - NCT03327675Recruiting
PET imaging test to plan personalized prostate cancer treatment
This trial tests a high-precision scan that uses a prostate cancer marker to show where cancer may be. The goal is to use the scan results to better plan treatment, especially around surgery and lymph nodes, in certain patients with prostate cancer.
LeuvenAges 18 years+ - NCT03594760RecruitingPhase 3
PSMA PET scan study using advanced computer imaging in prostate cancer
This Phase 3 study looks at how a PSMA PET scan can predict how prostate cancer will progress and how well treatment is working. If your doctor at CHUM orders this scan, you may be able to join to help refine better predictions for future patients.
Montreal, QuebecAges 18 years+ - NCT03861676RecruitingEarly Phase 1
PET-guided targeted radiation for early prostate cancer
This early-phase study tests a precise, targeted radiation treatment for prostate cancer, using a special PET scan to help plan exactly where to treat. It may help reduce the amount of radiation to surrounding tissues while treating the cancer.
Baltimore, MarylandAges 18–100 - NCT04035642Recruiting
Single high-dose MRI-guided radiation for intermediate prostate cancer
This trial tests whether a single, image-guided radiation treatment can treat intermediate-risk prostate cancer while better protecting the urethra (the urine tube). It may help patients get effective cancer control with potentially fewer urinary side effects, depending on the results.
LisbonAges 18 years+ - NCT04271579Recruiting
Surgery for early prostate cancer spread seen on PSMA PET
This trial studies whether operating on a small, one-sided (unilateral) area of prostate cancer spread in the pelvic lymph nodes—found on a PSMA PET scan—can help control recurrence. It’s meant for people whose PSA is still low and whose spread appears limited on the scan.
HamburgAges 18–75 - NCT04642027RecruitingPhase 3
PSMA scan-guided salvage radiation after prostate surgery
This trial tests whether using a specialized PSMA PET scan to guide radiation can better treat prostate cancer that returns after prostate surgery. It targets the “prostate bed” area with a shorter, stronger radiation schedule (hypofractionated) to control rising PSA levels.
Arnhem, GelderlandAges 18–80 - NCT04794777RecruitingPhase 3
Tests targeted scans and rescue radiation for returning prostate cancer
This trial studies whether a targeted scan (PSMA PET/CT) can help doctors choose the best “salvage” radiation treatment when prostate cancer comes back by PSA blood tests after surgery. It may help some people avoid under- or over-treating the areas where the cancer is returning.
Gothenburg, GöteborgAges 18 years+ - NCT04868604RecruitingPhase 1/Phase 2
Copper PSMA scan and treatment for prostate cancer in men on low testosterone
This trial tests a PSMA-targeted copper medicine used after a special PSMA PET/CT scan to find and treat prostate cancer that has spread. It’s for men whose testosterone is already very low and whose cancer is growing despite hormone-blocking medicines like enzalutamide or abiraterone.
Stanford, CaliforniaAges 18 years+ - NCT04946370RecruitingPhase 1/Phase 2
Pembrolizumab plus prostate cancer drug, with or without radiation
This early-phase trial tests pembrolizumab (an immune therapy) plus an androgen-receptor–blocking prostate cancer drug, and possibly a targeted radiation treatment. It’s for men with prostate cancer that has spread and keeps worsening despite standard hormone therapy, aiming to shrink tumors and improve control of the disease.
Boston, MassachusettsAges 18 years+ - NCT05022914Recruiting
PSMA PET/CT scan for PSA relapse after prostate surgery
This trial looks at using a PSMA PET/CT scan to better re-check cancer activity in men whose PSA has started rising after prostate removal. If you qualify, the scan may help doctors choose the next best treatment step.
FlorenceAges 18 years+ - NCT05398302RecruitingPhase 1
Biopsies during prostate cancer treatment to study resistance
This early study uses image-guided biopsies (small tissue samples taken with imaging) to learn why metastatic prostate cancer may stop responding to PSMA radioligand therapy. The results may help doctors understand resistance and improve future treatments.
Los Angeles, CaliforniaAges Any age - NCT05435495Recruiting
Study why PSMA radioligand therapy stops working
This study looks at tissue samples from tumors to understand how and why PSMA radioligand therapy may become less effective. If you have PSMA-avid cancer lesions that can be biopsied, the trial may help researchers find ways to improve treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT05647564Recruiting
PET/CT scan to study why prostate cancer resists treatment
This study uses a PET/CT scan to learn how and why prostate cancer becomes resistant to treatment. It may help researchers better match future therapy choices for people whose prostate cancer is progressing.
Madison, WisconsinAges 18 years+ - NCT05806515RecruitingPhase 2
Carboplatin before surgery for high-risk BRCA prostate cancer
This trial tests giving the chemotherapy drug carboplatin before surgery to treat people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene change. The goal is to shrink or control the cancer before an operation and improve outcomes.
Anchorage, AlaskaAges 18 years+ - NCT05948657Recruiting
PSMA PET-CT scan for men on prostate cancer surveillance
This study checks whether a special prostate scan called PSMA PET-CT (along with standard monitoring scans) can help guide care while you are on “active surveillance” instead of immediate treatment. It may help doctors track low-risk prostate cancer changes more accurately over time.
Los Angeles, CaliforniaAges 18 years+ - NCT06062745RecruitingPhase 1
PET scan study for prostate cancer with low PSMA or neuroendocrine features
This study tests a special PET scan (fluciclovine) to see if it can better detect prostate cancer that has low PSMA levels or has changed to a neuroendocrine type. It may help find tumors that standard PSMA scans miss.
Boston, MassachusettsAges 18 years+ - NCT06099093RecruitingPhase 4
PSMA PET scan before standard therapy for advanced prostate cancer
This trial will test if a special PET scan (18F-DCFPyL) can help doctors plan your treatment with a radioactive medicine called 177Lu-vipivotide tetraxetan. You are eligible if you already qualify for that standard therapy and have had a prior PSMA PET scan showing at least one active cancer site.
Boston, MassachusettsAges 18 years+
Hear when a new PSMA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psma?
- Yes. Clin2 currently lists 197 recruiting psma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.